source
- Novo Nordisk halts two more late-stage heart failure trials, calling IL-6 an invalid targetNovo Nordisk said it is ending two late-stage heart-failure studies, HERMES and ATHENA, that were testing its IL-6 inhibitor ziltivekimab. The company cited a recommendation from the Data Monitorin…
- Novartis' experimental drug fails pivotal trial for rare neuromuscular diseaseNovartis reported that its experimental therapy for a rare neuromuscular disorder did not improve muscle function in a pivotal study, missing its primary endpoints. The failure represents the comp…